JP2007504830A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504830A5
JP2007504830A5 JP2006526347A JP2006526347A JP2007504830A5 JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5 JP 2006526347 A JP2006526347 A JP 2006526347A JP 2006526347 A JP2006526347 A JP 2006526347A JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5
Authority
JP
Japan
Prior art keywords
compound according
compound
composition
oligonucleotide
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006526347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504830A (ja
JP4690324B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/029718 external-priority patent/WO2005023994A2/en
Publication of JP2007504830A publication Critical patent/JP2007504830A/ja
Publication of JP2007504830A5 publication Critical patent/JP2007504830A5/ja
Application granted granted Critical
Publication of JP4690324B2 publication Critical patent/JP4690324B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006526347A 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド Expired - Lifetime JP4690324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50150903P 2003-09-09 2003-09-09
US60/501,509 2003-09-09
PCT/US2004/029718 WO2005023994A2 (en) 2003-09-09 2004-09-09 Modified oligonucleotides for telomerase inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010286755A Division JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2007504830A JP2007504830A (ja) 2007-03-08
JP2007504830A5 true JP2007504830A5 (enExample) 2007-10-11
JP4690324B2 JP4690324B2 (ja) 2011-06-01

Family

ID=34273050

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Country Status (19)

Country Link
US (8) US7494982B2 (enExample)
EP (3) EP3682903A1 (enExample)
JP (10) JP4690324B2 (enExample)
KR (3) KR20060132802A (enExample)
CN (2) CN101293908B (enExample)
AU (2) AU2004271215B2 (enExample)
BR (1) BRPI0414222B8 (enExample)
CA (1) CA2536015C (enExample)
CY (2) CY1120113T1 (enExample)
DK (2) DK3342425T3 (enExample)
ES (2) ES2662196T3 (enExample)
HU (2) HUE048359T2 (enExample)
IL (1) IL173747A (enExample)
MX (1) MXPA06002660A (enExample)
NZ (1) NZ545516A (enExample)
PL (2) PL1667522T3 (enExample)
PT (2) PT1667522T (enExample)
SI (2) SI3342425T1 (enExample)
WO (1) WO2005023994A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101293908B (zh) 2003-09-09 2015-05-06 杰龙公司 用于端粒酶抑制的改性寡核苷酸
EP1694842B1 (en) 2003-11-04 2011-03-23 Geron Corporation Rna amidates and thioamidates for rnai
HUE037166T2 (hu) 2004-07-02 2018-08-28 Geron Corp Védett 3'-amino-nukleozid monomerek szintézise
EP1876893B1 (en) * 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP4600359A2 (en) * 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
KR101488800B1 (ko) 2007-02-09 2015-02-04 노오쓰웨스턴 유니버시티 세포내 타겟 검출용 입자
WO2008112129A2 (en) 2007-03-09 2008-09-18 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
US8202983B2 (en) 2007-05-10 2012-06-19 Agilent Technologies, Inc. Thiocarbon-protecting groups for RNA synthesis
WO2008151049A2 (en) 2007-05-30 2008-12-11 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
TW200927177A (en) * 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
MX2011000100A (es) * 2008-07-02 2011-02-25 Enzon Pharmaceuticals Inc Antagonistas del acido ribonucleico que se dirigen a la proteina de choque termico 27.
EP2175023A1 (en) * 2008-07-31 2010-04-14 The University of Zurich Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
PT3330383T (pt) 2008-10-17 2020-05-06 Geron Corp Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
DK2365803T3 (en) 2008-11-24 2018-01-22 Univ Northwestern POLYVALENT RNA NANOPARTICLE COMPOSITIONS
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
WO2011079290A1 (en) * 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
US9624542B2 (en) 2011-03-28 2017-04-18 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. キラル制御
WO2014066851A1 (en) 2012-10-26 2014-05-01 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
EP3495495B1 (en) 2012-11-30 2020-12-23 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
LT3646876T (lt) 2012-12-07 2024-05-10 Geron Corporation Telomerazės inhibitorius imetelstatas, skirtas mieloproliferacinių sutrikimų ir mieloproliferacinių navikų gydymui
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SI2959005T1 (sl) 2013-02-22 2022-01-31 The Board Of Trustees Of The Leland Stanford Junior University Medicinska uporaba v zvezi z ekstenzijo telomera
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN107427592A (zh) 2015-01-05 2017-12-01 株式会社露太利温 使用luterion抑制癌细胞中端粒酶的方法
TWI736532B (zh) * 2015-04-23 2021-08-21 美商傑龍公司 使用多價陽離子鹽組合物之聚核苷酸製備方法
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
EP3650546A1 (en) 2015-07-29 2020-05-13 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutic oligonucleotides
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN110945005A (zh) * 2017-04-20 2020-03-31 新特纳股份公司 包含三环dna核苷的修饰的寡聚化合物及其用途
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
SMT202100701T1 (it) 2017-07-10 2022-01-10 Geron Corp Processo migliorato per preparare imetelstat
US12171778B2 (en) 2017-07-28 2024-12-24 Geron Corporation Methods of treating myelodysplastic syndrome
JP7353301B2 (ja) 2018-05-07 2023-09-29 アルニラム ファーマスーティカルズ インコーポレイテッド 肝臓外送達
EP3887537A4 (en) 2018-11-29 2023-04-12 Geron Corporation METHODS OF TREATING MYELODYSPLASTIC SYNDROME
US20220370491A1 (en) * 2019-09-18 2022-11-24 National University Corporation Tokyo Medical And Dental University Nucleic acid complex
AU2020372865A1 (en) * 2019-10-28 2022-05-26 Geron Corporation Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same
MX2022005007A (es) 2019-10-28 2022-08-08 Geron Corp Sólidos cristalinos de 3-palmitoil-amido-1, 2-propanodiol y 3-palmitoil-amido-2-hidroxi-1-dimetoxitrifenilmetileter-propano y métodos para elaborarlos y usarlos.
CA3181682A1 (en) 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
JPWO2022186350A1 (enExample) * 2021-03-03 2022-09-09
WO2023141534A1 (en) 2022-01-19 2023-07-27 Northwestern University Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
CA2049028A1 (en) * 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) * 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) * 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US6235886B1 (en) * 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
CA2174425A1 (en) * 1993-10-18 1995-04-27 Graham Leslie Barrett A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
WO1995025814A1 (en) 1994-03-18 1995-09-28 Lynx Therapeutics, Inc. Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
CA2194393C (en) 1994-07-07 2002-06-25 Bryant Villeponteau Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
WO1996014277A1 (en) 1994-11-07 1996-05-17 Hybridon, Inc. Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en) * 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
DE60038495T2 (de) 1999-09-10 2009-04-09 Geron Corp., Menlo Park Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
CN101293908B (zh) 2003-09-09 2015-05-06 杰龙公司 用于端粒酶抑制的改性寡核苷酸
HUE037166T2 (hu) 2004-07-02 2018-08-28 Geron Corp Védett 3'-amino-nukleozid monomerek szintézise
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP4600359A2 (en) 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2007504830A5 (enExample)
JP2011092201A5 (enExample)
JP2023113843A5 (enExample)
JP6758335B2 (ja) テロメラーゼ阻害のための改変オリゴヌクレオチド
US5872107A (en) Treatment of urogenital cancer with boron neutron capture therapy
JP2009524696A5 (enExample)
US6583122B2 (en) Nucleosides and oligonucleotides containing boron clusters
JP2020022483A5 (enExample)
JP2020172488A (ja) Pd−l1発現低減用のオリゴヌクレオチド
JP2019511491A5 (enExample)
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
JP2016502858A5 (enExample)
JP2021090458A5 (enExample)
JP2015504650A5 (enExample)
JP2013510561A5 (enExample)
HRP20110352T1 (hr) Antisens olinukleotidi za induciranje zaobilaženja egzona i postupci njihove upotrebe
JP2021500025A5 (enExample)
JP2003523739A5 (enExample)
TWI762732B (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
CN1211923A (zh) 增强生物分子的细胞摄取的配体
JP2010505741A5 (enExample)
CA2303229A1 (en) Pentopyranosylnucleoside, its preparation and use
JP2008513513A5 (enExample)
JP2021072862A5 (enExample)
JP2005525991A5 (enExample)